<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lubiprostone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lubiprostone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lubiprostone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11557" href="/d/html/11557.html" rel="external">see "Lubiprostone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2609746"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amitiza [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2609750"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Chloride Channel Activator;</li>
<li>
                        Gastrointestinal Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F2610838"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f7d0405-0daa-4433-ac8b-56835ffe8655">Chronic idiopathic constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic idiopathic constipation: </b>
<b>Oral:</b> 24 mcg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9895d84-f23d-4ab8-b478-fe854563cc86">Irritable bowel syndrome with constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with constipation (females ≥18 years old; males [off label]): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with persistent constipation refractory to osmotic laxatives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 8 mcg twice daily; may require ≥2 months for symptom improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591','lexi-content-ref-22251419','lexi-content-ref-19006537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591','lexi-content-ref-22251419','lexi-content-ref-19006537'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee392cb0-53e9-4092-abcf-46fc1f9a8332">Opioid-induced constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid-induced constipation:</b>
<b>Oral:</b> 24 mcg twice daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992027"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989322"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild hepatic impairment (Child-Pugh class A):</b>  No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Moderate hepatic impairment (Child-Pugh class B): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic idiopathic constipation or opioid-induced constipation:</i> Initial: 16 mcg twice daily; may increase to 24 mcg twice daily if tolerated and an adequate response has not been obtained with lower dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Irritable bowel syndrome with constipation:</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe hepatic impairment (Child-Pugh class C):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic idiopathic constipation or opioid-induced constipation:</i> Initial: 8 mcg twice daily; may increase to 16 to 24 mcg twice daily if tolerated and an adequate response has not been obtained with lower dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Irritable bowel syndrome with constipation:</i> Initial: 8 mcg once daily; may increase to 8 mcg twice daily if tolerated and an adequate response has not been obtained at lower dosage.</p></div>
<div class="block doe drugH1Div" id="F2610839"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F2609759"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (7% to 12%; severe diarrhea: ≤2%), nausea (8% to 29%, incidence lower in males; older adults: 19%; severe nausea: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2% to 11%)</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (≤2%), chest pain (≤2%), edema (3%), peripheral edema (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (3% to 6%), abdominal distress (3%), abdominal pain (4% to 8%), dyspepsia (2%), flatulence (4% to 6%), loose stools (3%), vomiting (3%), xerostomia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%), fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, erythema of skin, hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, bowel urgency, decreased appetite, dysgeusia, eructation, fecal incontinence, frequent bowel movements, gastritis, gastroesophageal reflux disease</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Pollakiuria, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, depression, fibromyalgia syndrome, lethargy, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling, muscle cramps, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, pharyngolaryngeal pain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bloody diarrhea (Anton 2017), ischemic colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Anton 2017), asthenia, back pain (Anton 2017), muscle spasm, neck pain (Anton 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (Anton 2017)</p></div>
<div class="block coi drugH1Div" id="F2609755"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known or suspected mechanical gastrointestinal (GI) obstruction</p></div>
<div class="block war drugH1Div" id="F2609756"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dyspnea: Has been observed with use; often described as chest tightness and difficulty in taking a breath; generally occurs as an acute onset (within 30 to 60 minutes following the first dose) and resolves within a few hours; however, has been frequently reported with subsequent dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nausea: Nausea may occur; administer with food to reduce symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope/hypotension: May occur (some resulting in hospitalization) and generally resolved following discontinuation or prior to the next dose; reoccurrence has been reported with subsequent doses. Most cases occurred when taking 24 mcg twice daily, within an hour after the first dose or subsequent doses, or during concomitant use of medications known to decrease blood pressure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: Avoid use in patients with severe diarrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal obstruction: Symptoms of mechanical GI obstruction should be evaluated before prescribing this medicine; use is contraindicated in patients with bowel obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Patients with moderate-to-severe hepatic impairment (Child-Pugh class B or C) have higher systemic drug exposure; dosage adjustment may be recommended, depending on the indication and severity of hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Males: Not approved for use in males with irritable bowel syndrome with constipation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Efficacy of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (eg, methadone) has not been established.</p></div>
<div class="block foc drugH1Div" id="F2610846"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amitiza: 8 mcg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amitiza: 24 mcg [DSC] [contains fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mcg, 24 mcg</p></div>
<div class="block geq drugH1Div" id="F2609748"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422176"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lubiprostone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mcg (per each): $6.68 - $7.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24 mcg (per each): $6.68 - $7.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F2610844"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food and water. Swallow whole; do not break or chew.</p></div>
<div class="block use drugH1Div" id="F2609751"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic idiopathic constipation:</b> Treatment of chronic idiopathic constipation (CIC) in adults</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with constipation:</b> Treatment of irritable bowel syndrome (IBS) with constipation in women ≥18 years of age</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid-induced constipation:</b> Treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.</p></div>
<div class="block off-label drugH1Div" id="F57319019"><span class="drugH1">Use: Off-Label: Adult</span><p>Irritable bowel syndrome with constipation (male)</p></div>
<div class="block cyt drugH1Div" id="F13299620"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221379"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May diminish the therapeutic effect of Lubiprostone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May diminish the therapeutic effect of Lubiprostone.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2609753"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F15788822"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if lubiprostone or its active metabolite are present in breast milk. The manufacturer recommends that breastfed infants be monitored for diarrhea when administering lubiprostone to breastfeeding women. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F2610843"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food and water to decrease nausea.</p></div>
<div class="block pha drugH1Div" id="F2610828"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A chloride channel activator that acts locally on the apical membrane of the gastrointestinal tract to increase intestinal fluid secretion and improve fecal transit. This action bypasses the antisecretory effects of opiates, which suppress secretomotor neuron excitability.</p></div>
<div class="block phk drugH1Div" id="F2610830"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Systemic: Parent drug: Poor (below levels of detection); Active metabolite (M3): Low</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Minimal beyond GI tissue</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~94%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapid and extensive within stomach and jejunum by carbonyl reductase to M3 (active metabolite) and others</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Minimal</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: M3: 0.9 to 1.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: M3: ~1.1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Parent drug and M3: Feces (trace amounts)</p></div>
<div class="block phksp drugH1Div" id="F51153992"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> and AUC of active metabolite M3 are increased in patients with moderate-to-severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F14721643"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Gutfix | Gutlax | Laxana | Lubigut | Lubilax | Lubistone</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Moviprost</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amiprostone | Lunaprist</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Lubilax | Lubowel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amitiza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Amitiza (lubiprostone) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22323990">
<a name="22323990"></a>Anbardan SJ, Daryani NE, Fereshtehnejad SM, Taba Taba Vakili S, Keramati MR, Ajdarkosh H. Gender role in irritable bowel syndrome: a comparison of irritable bowel syndrome module (ROME III) between male and female patients. <i>J Neurogastroenterol Motil</i>. 2012;18(1):70-77. doi:10.5056/jnm.2012.18.1.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/22323990/pubmed" id="22323990" target="_blank">22323990</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Anton C. Adverse effects of laxatives: update. Wolters Kluwer Adverse Drug Reaction Bulletin. 2017;303.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27669680">
<a name="27669680"></a>Chang L, Chey WD, Drossman D, et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. <i>Aliment Pharmacol Ther</i>. 2016;44(10):1114-1122. doi:10.1111/apt.13807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/27669680/pubmed" id="27669680" target="_blank">27669680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738724">
<a name="35738724"></a>Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. <i>Gastroenterology</i>. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/35738724/pubmed" id="35738724" target="_blank">35738724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22251419">
<a name="22251419"></a>Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. <i>Aliment Pharmacol Ther</i>. 2012;35(5):587-599. doi:10.1111/j.1365-2036.2011.04983.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/22251419/pubmed" id="22251419" target="_blank">22251419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19006537">
<a name="19006537"></a>Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. <i>Aliment Pharmacol Ther</i>. 2009;29(3):329-341. doi:10.1111/j.1365-2036.2008.03881.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/19006537/pubmed" id="19006537" target="_blank">19006537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30084233">
<a name="30084233"></a>Fukudo S, Miwa H, Nakajima A, et al. Dose-finding study of linaclotide in Japanese patients with chronic constipation: a phase II randomized, double-blind, and placebo-controlled study. <i>Neurogastroenterol Motil</i>. 2018;30(12):e13442. doi:10.1111/nmo.13442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/30084233/pubmed" id="30084233" target="_blank">30084233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18248656">
<a name="18248656"></a>Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. <i>Aliment Pharmacol Ther</i>. 2008;27(8):685-696. doi:10.1111/j.1365-2036.2008.03629.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/18248656/pubmed" id="18248656" target="_blank">18248656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509103">
<a name="17509103"></a>Johanson JF and Ueno R, “Lubiprostone, a Locally Acting Chloride Channel Activator, In Adult Patients With Chronic Constipation: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety,” <i>Aliment Pharmacol Ther</i>, 2007, 25(11):1351-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/17509103/pubmed" id="17509103" target="_blank">17509103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022721">
<a name="32022721"></a>Shah ED, Suresh S, Jou J, Chey WD, Stidham RW. Evaluating when and why patients discontinue chronic therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation. <i>Am J Gastroenterol</i>. 2020;115(4):596-602. doi:10.14309/ajg.0000000000000530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/32022721/pubmed" id="32022721" target="_blank">32022721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 25, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10195 Version 208.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
